Effects of Bevacizumab combined with XELOX chemotherapy regimen in treatment of elderly patients with colon cancer
Objective:To observe effects of Bevacizumab combined with XELOX chemotherapy regimen in treatment of elderly patients with colon cancer.Methods:A prospective study was conducted on 68 elderly patients with colon cancer admitted to this hospital from December 2022 to December 2023.According to the random number table method,they were divided into control group and study group,34 cases in each group.The control group was treated with XELOX chemotherapy regimen,while the study group was treated with Bevacizumab on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[carbohydrate antigen 199(CA19-9),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)]and vascular endothelial function indexes[vascular endothelial growth factor(VEGF),cyclooxygenase-2(COX-2),matrix metalloproteinase-9(MMP-9)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease remission rate and the disease control rate of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CA19-9,CEA and CA125 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of VEGF,COX-2 and MMP-9 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bevacizumab combined with XELOX chemotherapy in the treatment of the elderly patients with colon cancer can improve the disease remission rate and the disease control rate,and reduce the levels of tumor markers and vascular endothelial function indexes.Moreover,it is superior to simple XELOX chemotherapy.
万方数据
维普
